The coumarin scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory

Alkondon, 1993, Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons, J Pharmacol Exp Ther, 265, 1455 Alkondon, 2004, The nicotinic acetylcholine receptor subtypes and their function in the hippocampus and cerebral cortex, Prog Brain Res, 145, 109, 10.1016/S0079-6123(03)45007-3 Bartolini, 1996, Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions, Pharmacol Biochem Behav, 53, 277, 10.1016/0091-3057(95)02021-7 Bertholet, 1991, Spatial and non-spatial spontaneous alternation and hippocampal mossy fibre distribution in nine inbred mouse strains, Behav Brain Res, 43, 197, 10.1016/S0166-4328(05)80071-3 Blesa, 2003, Galantamine provides sustained benefits in patients with “advanced moderate” Alzheimer's disease for at least 12 months, Dement Geriatr Cogn Disord, 15, 79, 10.1159/000067974 Bliss, 1993, A synaptic model of memory: long-term potentiation in hippocampus, Nature, 361, 31, 10.1038/361031a0 Boess, 2007, The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents, J Pharmacol Exp Ther, 321, 716, 10.1124/jpet.106.118976 Bontempi, 2003, Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors, Neuropsychopharmacology, 28, 1235, 10.1038/sj.npp.1300150 Brühlmann, 2001, Coumarin derivatives as dual inhibitors of acetylcholinesterase and momoamine oxidase, J Med Chem, 44, 3195, 10.1021/jm010894d Buckingham, 2009, Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection, Pharmacol Rev, 61, 39, 10.1124/pr.108.000562 Calixto, 2003, Anti-inflammatory compounds of plant origin, Planta Med, 69, 973 Capone, 1999, Effects of the novel acetylcholinesterase inhibitor N-octyl-1,2,3, 4-tetrahydro-9-aminoacridine on locomotor activity and avoidance learning in mice, Neurobiol Learn Mem, 71, 301, 10.1006/nlme.1998.3883 Capron, 2006, The characteristics of LTP in hippocampal slices are dependent on slice-recovery conditions, Learn Mem, 13, 271, 10.1101/lm.135406 Carlsson, 1989, Marked locomotor stimulation in monoamine-depleted mice following treatment with atropine in combination with clonidine, J Neural Transm Park Dis Dement Sect, 1, 317, 10.1007/BF02263486 Chimenti, 2004, Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: biological activity and computational study, Bioorg Med Chem Lett, 14, 3697, 10.1016/j.bmcl.2004.05.010 Delatour, 1996, Prelimbic cortex specific lesions disrupt delayed-variable response tasks in the rat, Behav Neurosci, 110, 1282, 10.1037/0735-7044.110.6.1282 Dember, 1990, The search for cues and motives, 73 Desgranges, 1996, Memory disorders in Alzheimer's disease and the organization of human memory, Cortex, 32, 387, 10.1016/S0010-9452(96)80001-3 Dodart, 1997, Scopolamine-induced deficits in a two-trial object recognition task in mice, Neuroreport, 8, 1173, 10.1097/00001756-199703240-00023 Duffy, 2009, Spatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouse, Neuroscience, 161, 1091, 10.1016/j.neuroscience.2009.04.024 Egger, 1973, Ontogenetic aspects of central cholinergic involvement in spontaneous alternation behavior, Dev Psychobiol, 6, 289, 10.1002/dev.420060402 Einat, 1995, Perseveration without hyperlocomotion in a spontaneous alternation task in rats sensitized to the dopamine agonist quinpirole, Physiol Behav, 57, 55, 10.1016/0031-9384(94)00209-N Ennaceur, 1988, A new one-trial test for neurobiological studies of memory in rats, Behav Brain Res, 31, 47, 10.1016/0166-4328(88)90157-X Farah, 1992, Pharmacologically active phenylpropanoids from senra incana, Planta Med, 58, 14, 10.1055/s-2006-961380 Fernando, 1986, The role of dopamine in behavioral supersensitivity to muscarinic antagonists following cholinesterase inhibition, Life Sci, 39, 2169, 10.1016/0024-3205(86)90393-0 Flicker, 1985, Cognitive function in normal aging and early dementia, 2 Franklin, 1997 Froc, 2003, Reduced synaptic plasticity in the lateral perforant path input to the dentate gyrus of aged C57BL/6 mice, J Neurophysiol, 90, 32, 10.1152/jn.00105.2003 Fujii, 2001, Acute and chronic nicotine exposure reverse age-related declines in the induction of long-term potentiation in the rat hippocampus, Brain Res, 894, 347, 10.1016/S0006-8993(01)02057-1 Fujii, 2000, Inactivation of α7 ACh receptors and activation of non-α7 ACh receptors both contribute to long-term potentiation induction in the hippocampal CA1 region, Neurosci Lett, 286, 134, 10.1016/S0304-3940(00)01076-4 Fujioka, 1999, Antiproliferative constituents from umbelliferae plants, Chem Pharm Bull, 47, 96, 10.1248/cpb.47.96 Gainotti, 1998, Sensitivity and specificity of some neuropsychological markers of Alzheimer dementia, Alzheimer Dis Assoc Disord, 12, 152, 10.1097/00002093-199809000-00006 Garcia-Sanz, 2001, Superfusion of synaptosomes to study presynaptic mechanisms involved in neurotransmitter release from rat brain, Brain Res Brain Res Protoc, 7, 94, 10.1016/S1385-299X(00)00058-1 Ge, 2005, Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation, J Neurosci, 25, 6084, 10.1523/JNEUROSCI.0542-05.2005 Gerlai, 1998, A new continuous alternation task in T-maze detects hippocampal dysfunction in mice, Behav Brain Res, 95, 91, 10.1016/S0166-4328(97)00214-3 Hoerr, 2002, Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment, CNS Drug Rev, 8, 143, 10.1111/j.1527-3458.2002.tb00220.x Hornick, 2008, Extracts and constituents of leontopodium alpinum enhance cholinergic transmission: brain ACh increasing and memory improving properties, Biochem Pharmacol, 76, 236, 10.1016/j.bcp.2008.04.015 Itoh, 1993, Dopaminergic involvement in the improving effects of dynorphin A-(1–13) on scopolamine-induced impairment of alternation performance, Eur J Pharmacol, 241, 99, 10.1016/0014-2999(93)90938-E Jones, 1999, Nicotinic receptors in the brain: correlating physiology with function, Trends Neurosci, 22, 555, 10.1016/S0166-2236(99)01471-X Kang, 1999, Scopoletin: an inducible nitric oxide synthesis inhibitory active constituent from artemisia feddei, Planta Med, 65, 400, 10.1055/s-1999-14014 Kim, 2007, Nodakenin, a coumarin compound, ameliorates scopolamine-induced memory disruption in mice, Life Sci, 80, 1944, 10.1016/j.lfs.2007.02.023 Kim, 1999, In vitro inducible nitric oxide synthesis inhibitory active constituents from fraxinus rhynchophylla, Planta Med, 65, 656, 10.1055/s-2006-960840 Kokkinidis, 1976, Interaction between cholinergic and catecholaminergic agents in a spontaneous alternation task, Psychopharmacology, 48, 261, 10.1007/BF00496859 Lagostena, 2008, The partial alpha7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus, Neuropharmacology, 54, 676, 10.1016/j.neuropharm.2007.11.016 Lee, 2003, Associative and recognition memory for novel objects in dementia: implications for diagnosis, Eur J Neurosci, 18, 1660, 10.1046/j.1460-9568.2003.02883.x Lilienfeld, 2000, Galantamine: additional benefits to patients with Alzheimer's disease, Dement Geriatr Cogn Disord, 11, 19, 10.1159/000051228 Lin, 2008, Structure-activity relationship of coumarin derivatives on xanthine oxidase-inhibiting and free radical-scavenging activities, Biochem Pharmacol, 75, 1416, 10.1016/j.bcp.2007.11.023 Liu, 2007, Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model, FASEB J, 21, 61, 10.1096/fj.06-5841com Lynch, 2002, Memory enhancement: the search for mechanism-based drugs, Nat Neurosci, 5, 1035, 10.1038/nn935 Maelicke, 2000, Allosterically potentiating ligands of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease, Behav Brain Res, 113, 199, 10.1016/S0166-4328(00)00214-X Mann, 2003, Novel modulatory mechanisms reveled by the sustained application of nicotine in the guinea-pig hippocampus in vitro, J Physiol, 551, 539, 10.1113/jphysiol.2003.045492 Marchi, 1999, Nicotinic receptors modulating ACh release in rat cortical synaptosomes: role of Ca2+ions and their function and desesnitization, Neurochem Int, 34, 319, 10.1016/S0197-0186(99)00015-7 Marchi, 1983, Is acetylcholine release from striatal nerve endings regulated by muscarinic autoreceptors?, Eur J Pharmacol, 91, 63, 10.1016/0014-2999(83)90362-X Martin, 2002, New life in an old idea: the synaptic plasticity and memory hypothesis revisited, Hippocampus, 12, 609, 10.1002/hipo.10107 Matsuyama, 2003, Epibatidine induces long-term potentiation (LTP) via activation of alpha4beta2 nicotinicacetylcholine receptors (nAChRs) in vivo in the intact mouse dentate gyrus: both alpha7 and alpha4beta2 nAChRs essential to nicotinic LTP, J Pharmacol Sci, 93, 180, 10.1254/jphs.93.180 McFarland, 1989, Effects of scopolamine, d-amphetamine, and apomorphine on alternation and position biases, Pharmacol Biochem Behav, 32, 723, 10.1016/0091-3057(89)90024-5 Meyers, 1964, The effect of cholinergic drugs on spontaneous alternation in rats, Arch Int Pharmacodyn, 150, 3 Moriguchi, 2009, Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation, Hippocampus, 19, 844, 10.1002/hipo.20572 Muschietti, 2001, Phenolic compounds with anti-inflammatory activity from eupatorium buniifolium, Planta Med, 67, 743, 10.1055/s-2001-18355 Nakauchi, 2007, Nicotine gates long-term potentiation in the hipppocampal CA1 region via the activation of α2* nicotinic ACh receptors, Eur J Neurosci, 25, 2666, 10.1111/j.1460-9568.2007.05513.x Newhouse, 2001, Nicotinic treatment of Alzheimer's disease, Biol Psychiatry, 49, 268, 10.1016/S0006-3223(00)01069-6 Newman, 1999, The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample, J Affect Disord, 52, 169, 10.1016/S0165-0327(98)00070-6 Onor, 2007, Rivastigmine in the treatment of Alzheimer's disease: an update, Clin Interv Aging, 2, 17, 10.2147/ciia.2007.2.1.17 Palmer, 1988, Possible neurotransmitter basis of behavioral changes in Alzheimer's disease, Ann Neurol, 23, 616, 10.1002/ana.410230616 Papke, 2008, Extending the analysis of nicotinic receptor antagonists with the study of α6 nicotinic receptor subunit chimeras, Neuropharmacology, 54, 1189, 10.1016/j.neuropharm.2008.03.010 Petersen, 2000, Memory and MRI-based hippocampal volumes in aging and AD, Neurology, 54, 581, 10.1212/WNL.54.3.581 Pichat, 2007, SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia, Neuropsychopharmacology, 32, 17, 10.1038/sj.npp.1301188 Prut, 2003, The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review, Eur J Pharmacol, 463, 3, 10.1016/S0014-2999(03)01272-X Puma, 1999, Nicotine improves memory in an object recognition task in rats, Eur Neuropsychopharmacol, 9, 323, 10.1016/S0924-977X(99)00002-4 Qi, 2007, Neurochem Int, 51, 377, 10.1016/j.neuint.2007.04.002 Raiteri, 2000, Synaptosomes still viable after 25 years of superfusion, Neurochem Res, 25, 1265, 10.1023/A:1007648229795 Raiteri, 1974, A simple apparatus for studying the release of neurotransmitters from synaptosomes, Eur J Pharmacol, 25, 411, 10.1016/0014-2999(74)90272-6 Remy, 2005, Verbal episodic memory impairment in Alzheimer's disease: a combined structural and functional MRI study, Neuroimage, 25, 253, 10.1016/j.neuroimage.2004.10.045 Rispoli, 2006, Choline pivaloyl ester strengthened the benefit effects of tacrine and galantamine on electroencephalographic and cognitive performances in nucleus basalis magnocellularis-lesioned and aged rats, Pharmacol Biochem Behav, 84, 453, 10.1016/j.pbb.2006.06.009 Rollinger, 2004, Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products, J Med Chem, 47, 6248, 10.1021/jm049655r Roman, 2004, Potentiation effects of (+/-)huprine X, a new acetylcholinesterase inhibitor, on nicotinic receptors in rat cortical synaptosomes, Neuropharmacology, 46, 95, 10.1016/j.neuropharm.2003.08.005 Roncarati, 2009, Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders, J Pharmacol Exp Ther, 329, 459, 10.1124/jpet.108.150094 Rosato-Siri, 2006, Nicotine-induced enhancement of synaptic plasticity at CA3-CA1 synapses requires GABAergic interneurons in adult anti-NGF mice, J Physiol, 576, 361, 10.1113/jphysiol.2006.114587 Sambeth, 2007, Cholinergic drugs affect novel object recognition in rats: relation with hippocampal EEG?, Eur J Pharmacol, 572, 151, 10.1016/j.ejphar.2007.06.018 Samochocki, 2003, Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors, J Pharmacol Exp Ther, 305, 1024, 10.1124/jpet.102.045773 Schoenmakers, 2009, Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver?, J Fam Pract, 26, 279, 10.1093/fampra/cmp024 Scott, 2000, Galantamine: a review of its use in Alzheimer's disease, Drugs, 60, 1095, 10.2165/00003495-200060050-00008 Shaw, 2003, Antioxidant properties of scopoletin isolated from sinomonium acutum, Phytother Res, 17, 823, 10.1002/ptr.1170 Shen, 2005, Synthesis and biological evaluation of functionalized coumarins as acetylcholinesterase inhibitors, Eur J Med Chem, 40, 1307, 10.1016/j.ejmech.2005.07.014 Sliwinski, 2004, Pregnenolone sulfate enhances long-term potentiation in CA1 in rat hippocampus slices through the modulation of N-methyl-d-aspartate receptors, J Neurosci Res, 78, 691, 10.1002/jnr.20332 Sonnen, 2008, Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models, Free Radic Biol Med, 45, 219, 10.1016/j.freeradbiomed.2008.04.022 Sonnen, 2009, Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking, Ann Neurol, 65, 226, 10.1002/ana.21508 Spowart-Manning, 2004, The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse, Behav Brain Res, 151, 37, 10.1016/j.bbr.2003.08.004 Stone, 1992, Glucose attenuation of scopolamine- and age-related deficits in spontaneous alternation behaviour and regional [3H]2-deoxy-glucose uptake in mice, Psychobiology, 20, 270, 10.3758/BF03332059 Storch, 1995, Physostigmine, galanthamine and codeine act as “noncompetitive nicotinic receptor agonists” on clonal rat pheochromocytoma cells, Eur J Pharmacol, 290, 207, 10.1016/0922-4106(95)00080-1 Stuppner, 2005 Syenkiewicz-Jarosz, 2000, The effects of physostigmine and cholinergic receptor ligands on novelty-induced neophobia, J Neural Transm, 107, 1403, 10.1007/s007020070004 Szerb, 1977, Release of [3H]acetylcholine from rat hippocampal slices: effect of septal lesions and graded concentrations of muscarinic agonists and antagonists, Brain Res, 128, 285, 10.1016/0006-8993(77)90995-7 Timmermann, 2007, An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo, J Pharmacol Exp Ther, 323, 294, 10.1124/jpet.107.120436 Tiyagi, 2005, Synthesis of novel amino and acetyl-amino-4-methylcoumarins and evaluation of their antioxidant activity, Eur J Med Chem, 40, 413, 10.1016/j.ejmech.2004.09.002 Toda, 2002, Inhibitory effects of phenylpropanoid metabolites on copper-induced protein oxidative modification of mice brain homogenate, in vitro, Biol Trace Elem Res, 85, 183, 10.1385/BTER:85:2:183 Tzavara, 2003, Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice, Mol Psychiatry, 8, 673, 10.1038/sj.mp.4001270 Ukai, 1995, Cholinergic receptor antagonists inhibit pirenzepine-induced dysfunction of spontaneous alternation performance in the mouse, Gen Pharmacol, 26, 1529, 10.1016/0306-3623(95)00038-0 Wang, 2007, The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems, Neuropsychopharmacology, 32, 1261, 10.1038/sj.npp.1301256 Willig, 1987, Short-term memory, exploration and locomotor activity in aged rats, Neurobiol Aging, 8, 393, 10.1016/0197-4580(87)90033-9 Wishka, 2006, Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure-activity relationship, J Med Chem, 49, 4425, 10.1021/jm0602413 Woodruff-Pak, 2002, Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia, Behav Cogn Neurosci Rev, 1, 5, 10.1177/1534582302001001002 Yun, 2001, Coumarins with monoamine oxidase inhibitory activity and antioxidative coumarino-lignans from hibiscus syriacus, J Nat Prod, 64, 1238, 10.1021/np0100946 Zhang, 2002, Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice, J Neurosci, 22, 1709, 10.1523/JNEUROSCI.22-05-01709.2002 Zhao, 2009, Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease, Neurochem Res, 34, 630, 10.1007/s11064-008-9900-9